PLUS THERAPEUTICS, INC. Annual Report: An Investor's Guide

Considering an investment in PLUS THERAPEUTICS, INC.? Let's cut through the jargon and explore their recent year, focusing on what truly matters for a clinical-stage biopharmaceutical company.

Business Overview: What They Do & Their Strategy PLUS THERAPEUTICS, INC. is a clinical-stage biopharmaceutical company that develops innovative targeted radiotherapeutics for cancer. Their core strategy focuses on advancing a pipeline of experimental treatments through research and development (R&D). This requires significant capital, and the company prioritizes securing the necessary funding for these intensive efforts. Their activities this past year clearly reflect this R&D-driven, capital-intensive approach.

Competitive Position The biopharmaceutical industry, especially in oncology, is intensely competitive and sees rapid technological advancements. PLUS THERAPEUTICS aims to establish its competitive position by developing innovative targeted radiotherapeutics that address specific unmet medical needs in cancer treatment. They leverage their proprietary technology and advance their pipeline through rigorous R&D. The acquisition of assets from Biocept, Inc. demonstrates their effort to expand technological capabilities or product offerings, thereby strengthening their competitive stance. Success in clinical trials, securing intellectual property, and achieving regulatory approvals are critical steps that differentiate their product candidates and enable them to compete effectively against established pharmaceutical companies and other emerging biotechs with significant resources and pipelines.

Financial Performance – A Snapshot As a clinical-stage company, PLUS THERAPEUTICS does not yet generate revenue from product sales. Consequently, significant operating losses and an accumulated deficit characterize their financial performance, which is typical for companies in this phase. For both 2024 and 2025, the company spent substantially on Research and Development (R&D) to advance its drug candidates, alongside General and Administrative (G&A) costs for day-to-day operations. The company's continuous need for external funding highlights its significant cash burn and the ongoing investment required to progress its pipeline.

Management's Discussion and Analysis (MD&A) Highlights: Key Developments & Milestones Management highlights the following key developments and milestones in their discussion of operations and financial condition:

Significant Funding Activities: The company actively raised capital, crucial for sustaining operations and R&D:

• Private Placements: They completed two significant private placements, one in May 2024 and another in March 2025, selling common stock and warrants (or pre-funded warrants). These placements directly injected cash into the company.
• Lincoln Park Capital Fund LLC Agreement: A Purchase Agreement with Lincoln Park Capital Fund LLC in 2025 offers a flexible funding mechanism, letting them sell common stock to Lincoln Park over time.
• Warrant-Related Agreements: Further Securities Purchase and Exchange Agreements in February 2025 also raised capital.
• Subsequent Public Offering: Highlighting their ongoing capital needs, the company announced a subsequent Underwritten Public Offering in January 2026.

Non-Dilutive Funding & External Validation:

• Grants and Awards: They received funding from the Cancer Prevention and Research Institute of Texas (CPRIT) and secured a Department of Defense (DoD) award in late 2024, extending into 2025. These grants are valuable because they provide non-dilutive capital, which means they don't dilute existing shareholders by issuing new shares.

Strategic Growth & Operational Readiness:

• Biocept Asset Acquisition: In April 2024, PLUS THERAPEUTICS acquired assets from Biocept. This move likely expands their oncology pipeline or enhances their diagnostic capabilities, strengthening their position in cancer treatment.
• Manufacturing Agreement: They signed a crucial Manufacturing Agreement with SpectronRX in November 2024. This vital step prepares them for the potential future production of their therapeutic candidates, showing progress toward commercialization.

Financial Health & Liquidity At the close of both 2024 and 2025, the company held cash reserves in U.S. Treasury Securities and Money Market Funds to fund operations. Their liabilities included standard Accounts Payable and Accrued Liabilities. To finance their activities, they used various debt instruments, such as Convertible Notes and a Term Loan active in 2025, as well as a Pershing Credit Facility in both 2024 and 2025. Their continuous reliance on both equity and debt financing highlights the significant capital requirements of their R&D-intensive business model.

Key Risks for Investors:

1. Funding & Dilution Risk: Frequent capital raises, while necessary, significantly dilute shareholders. Each new share issued reduces existing shareholders' ownership. The Purchase Agreement with Lincoln Park Capital Fund LLC carries specific risks: a stock price drop below certain thresholds (e.g., $0.75 or $0.50 per share) could severely hamper their ability to sell shares to Lincoln Park and raise crucial funds.
2. Clinical Trial Risk: As a clinical-stage biopharmaceutical company, PLUS THERAPEUTICS faces inherent drug development risks. Their success hinges on favorable clinical trial outcomes, which are often unpredictable and can fail at any stage.
3. Regulatory Approval Risk: Even with positive clinical trial results, regulatory approval from bodies like the FDA is not guaranteed. The approval process is rigorous, lengthy, and various factors can influence it.
4. Cash Burn & Liquidity Risk: Operating at a loss, the company maintains a high cash burn rate. Their continued existence depends on consistently raising sufficient capital through equity, debt, or grants. Failure to secure future funding could severely impact operations and pipeline advancement.
5. Competitive Landscape: The oncology market is highly competitive, with numerous established pharmaceutical companies and emerging biotechs vying for market share.
6. Intellectual Property: Protecting intellectual property is critical. Challenges to their patents or proprietary technology could undermine future commercial prospects.

Future Outlook Looking ahead, PLUS THERAPEUTICS clearly focuses on advancing its clinical pipeline and securing necessary funding, as evidenced by the planned January 2026 public offering. Continued grants and established manufacturing agreements suggest ongoing progress toward potential product delivery. Investors should closely monitor clinical trial milestones, regulatory progress, and their continued ability to raise capital to support ambitious development programs. These factors, along with the competitive and regulatory environment, will undoubtedly play a significant role in the company's future trajectory.